KRAS Inhibitor Resistance Confers a Targetable Vulnerability to Ferroptosis in Pancreatic Ductal Adenocarcinoma.

Acquisition of resistance to KRAS inhibitors in pancreatic ductal adenocarcinoma cells is linked to hypersensitivity to ferroptosis, driven by NR2F2-mediated lipid remodeling.

• Why it matters: KRAS inhibitor benefits in PDAC are limited by frequent resistance, leaving a need for vulnerabilities that emerge after resistance develops.
• What they did: The authors profiled lipids in resistant PDAC cells and found enrichment of polyunsaturated fatty acid-containing phosphatidylcholines with reduced monounsaturated species; they identified NR2F2 as a key determinant via changes in its regulatory-element occupancy and chromatin accessibility.
• The result: NR2F2-driven PUFA biosynthesis and phospholipid remodeling create a ferroptosis-prone lipid state, suggesting ferroptosis induction could target KRAS inhibitor-resistant PDAC.

AI summary of the abstract · may contain errors · not medical advice · read the paper.